Abstract
Vaginal atrophy is a common problem in women who have previously been treated for breast cancer. Endocrine therapy plays an essential role in the treatment of breast cancer. Systemic hormonal treatment is contraindicated. Topical oestrogens are an effective treatment for vaginal atrophy, but are poorly studied in this group of patients. Physicians are reluctant to recommend it because of the potential increase in the risk of recurrence. The sparse data available suggest that vaginal oestrogen may be used relatively safely by women who are in tamoxifen treatment, but should not be used by women who receive aromatase inhibitor treatment.
| Bidragets oversatte titel | Vaginal oestrogen therapy in women with hormone-sensitive breast cancer |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 173 |
| Udgave nummer | 9 |
| Sider (fra-til) | 648-51 |
| Antal sider | 4 |
| ISSN | 0041-5782 |
| Status | Udgivet - 28 feb. 2011 |
| Udgivet eksternt | Ja |
Emneord
- Administration, Intravaginal
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Atrophy
- Breast Neoplasms
- Estrogen Antagonists
- Estrogen Replacement Therapy
- Estrogens
- Female
- Humans
- Menopause
- Neoplasm Recurrence, Local
- Tamoxifen
- Vagina